btig

BTIG's Dane Leone downgraded Celgene Corporation (NASDAQ: CELG) from Buy to Neutral. Leone noted Celgene has made multiple innovate early stage investments "but…unsure of upside to current consensus estimates." The majority of the company's sales growth is dependent on...

The S&P 500 is once again up against the critical 2100 level that has proved difficult to break through for roughly a year now. According to BTIG analyst Katie Stockton, the market is likely in for a big move one way or the other in coming weeks. “We think a failed breakout is likely...

Shares of Palo Alto Networks Inc (NYSE: PANW) plunged 13 percent after the cybersecurity firm issued a weak fourth-quarter outlook despite reporting strong third-quarter results. But, BTIG is bullish on the company's long-term thesis and would be buyers on any weakness. Strong Quarter Palo Alto's...

Shares of LendingClub Corp (NYSE: LC) are down 42 percent since the company disclosed accounting irregularities with its Q1 earnings press release on May 6. Additional details were disclosed in the company's 10Q filed after Monday's close. BTIG analyst Mark Palmer points out the main...

Relypsa Inc (NASDAQ: RLYP) has released monthly Veltassa prescription trends for April, with paid prescriptions rising to 928 in the fourth full month following the launch of the drug and the company having dispensed 1,216 starter packs. BTIG’s Timothy Chiang maintains a Buy rating on the...

Agilent Technologies Inc (NYSE: A) reported its FY2Q16 results broadly ahead of expectations. BTIG’s Dane Leone reiterated a Buy rating for the company, with a price target of $50. The analyst commented that management would begin gaining credibility for “under-promising and over-...

BTIG analyst Joel Fishbein recently addressed a major elephant in the room for online advertisers like Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) and Facebook Inc (NASDAQ: FB): ad-blocking software. So far, the rise of Internet advertising has been meteoric, but could ad-blockers derail the...

Jack in the Box Inc. (NASDAQ: JACK) reported its 2QF16 results significantly ahead of expectations. BTIG’s Peter Saleh maintains a Buy rating on the company, while raising the price target from $79 to $85. Positive Trends Saleh explained that the 2Q beat was “aided by a few less common...

BTIG analyst Dane Leone likes Johnson & Johnson (NYSE: JNJ) and for good reason. Shares of the pharmaceutical firm have gained just over 11 percent year-to-date. The recent plateau in price appreciation, though, has broken Leone's conviction for a Buy recommendation. After the market...

BTIG's Hartaj Singh downgrades Epirus Biophramaceuticals Inc (NASDAQ: EPRS) from Buy to Neutral. Share were recently down about 18 percent at $0.88. Epirus made senior management changes Tuesday, as well as a change in strategy moving forward in the fiscal year. CEO Amit Munshi stepped down...

Shares of bluebird bio Inc (NASDAQ: BLUE) were trading lower by 5 percent mid-Thursday afternoon after the company reported its first-quarter results. Bluebird bio said that it lost $1.52 per share on revenue of $1.499 million during the quarter. Wall Street analysts were expecting the company to...

Morgan Stanley has downgraded On Deck Capital Inc (NYSE: ONDK) to Equal-Weight from Overweight, citing erosion of near-term profitability from changes in funding mix. "[W]e think fluctuations in institutional demand could limit origination growth potential beyond 2016 and push out any meaningful...

BTIG has downgraded Bruker Corporation (NASDAQ: BRKR) to Neutral from Outperform, saying the "margin story continues to play out but [we] are hesitant to expect upside to its current organic growth forecasts this early in 2016." The scientific equipment maker reported first quarter EPS of $0.21,...